BTAI Filings — Bioxcel Therapeutics, Inc. - FilingSpy
BTAI
Bioxcel Therapeutics, Inc.
A biopharmaceutical company that turns already-approved drugs into new treatments, using AI to "re-innovate" existing medicines. Its lead product, IGALMI, is a small dissolvable film placed under the tongue that calms sudden agitation in people with schizophrenia or bipolar disorder. Founded in 2017 and based in New Haven, Connecticut, the company skipped traditional venture funding and went straight to the public markets the following year — with a name that blends "bio" with a nod to accelerating drug development.
Cash falls to $12.8M, funding only through August 2026, as BioXcel races to close a strategic transaction by an August 21 lender deadline.
BioXcel is running out of time. IGALMI was $0.2 million in Q2 2026, up 52% from a year ago but still negligible, while the company burned $6.1 million in and ended the quarter with just $12.8 million in cash—enough to fund operations only through August 2026. The company's future now hinges entirely on closing a sale, merger, or other strategic transaction by an August 21, 2026, lender deadline, without which it may be forced to seek bankruptcy protection.
Key takeaways
Cash and equivalents fell to $12.8 million as of June 30, 2026, down 26% from a year earlier, and management again expressed substantial doubt about the company's ability to continue as a , stating the balance funds operations only through August 2026.
A in the Twelfth Amendment to the Credit Agreement requires the company to enter into definitive agreements for a strategic transaction acceptable to lenders by August 21, 2026, to address its $107.2 million in outstanding debt; the company is actively pursuing a sale, merger, or other transaction to avoid a potential bankruptcy filing.
Section summaries
Management's Discussion and Analysis
BioXcel faces substantial doubt as a going concern, with $13.8M cash and a lender deadline of Aug 21, 2026 to close a strategic transaction.
⌄
R&D expense fell 69% to $3.2M in Q2 2026, driven by the completion of the SERENITY At-Home Phase 3 trial and correlation study in 2025.
SG&A expense rose 28% to $7.2M in Q2 2026, primarily due to an 80% increase in professional fees for legal and consulting costs.
IGALMI net product was $0.2 million, up 52% , which management attributed to deeper group purchasing organization discounts and new contracts, though the absolute revenue remains minimal.
Research and development expense fell 69% to $3.2 million as the SERENITY At-Home Phase 3 trial and a correlation study completed in 2025, while selling, general and administrative expense rose 28% to $7.2 million on an 80% increase in professional fees for legal and consulting costs.
The FDA accepted the supplemental New Drug Application for at-home use of IGALMI with a PDUFA target action date of November 14, 2026, a regulatory catalyst that could support a label expansion but arrives months after the company's cash runs out.
fell to zero on the balance sheet as the remaining $97.5 million was reclassified to current liabilities, reflecting the imminent maturity and default risk under the Credit Agreement.
What changed
The Q1 FY2026 filing flagged whether the company would secure additional financing before cash ran out in Q2 2026: it did not. Cash fell from $17.2 million to $12.8 million, and the company is now pursuing a strategic transaction rather than a standalone capital raise.
The Q1 filing also flagged IGALMI trajectory to gauge whether the Q1 increase to $206,000 reflected sustainable demand: Q2 revenue was $0.2 million, essentially flat sequentially, suggesting the discount-driven volume strategy is not building meaningful commercial momentum.
The FY2025 10-K flagged FDA acceptance of the sNDA for at-home IGALMI: the FDA accepted the application and set a November 14, 2026 , but the regulatory milestone is now overshadowed by the immediate liquidity crisis.
The risk factors newly emphasize U.S. tariffs on imported patented pharmaceuticals effective July 31, 2026, which could materially increase manufacturing costs for IGALMI and its active ingredient—a that did not appear in prior filings.
What to watch
Whether the company announces a definitive agreement for a sale, merger, or other strategic transaction by the August 21, 2026, lender deadline, and on what terms, given the $12.8 million cash balance and $107.2 million in outstanding debt.
Any filing under Chapter 11 of the U.S. Bankruptcy Code if the company fails to close a strategic transaction and lenders do not grant further forbearance.
The FDA's review of the at-home IGALMI sNDA ahead of the November 14, 2026 , including any advisory committee meeting or information requests, though this is now secondary to the going-concern resolution.
The impact of newly effective U.S. tariffs on imported patented pharmaceuticals on IGALMI manufacturing costs and the company's ability to source the active ingredient economically.
IGALMI net product was $0.2M in Q2 2026, up from $0.1M a year ago, attributed to deeper discounts and new contracts.
The company is actively pursuing a sale, merger, or other strategic transaction to address its liquidity crisis and avoid a potential bankruptcy filing.
The FDA accepted an for IGALMI for at-home use with a of November 14, 2026, a key regulatory catalyst.
Cash used in operations was $17.9M for the first half of 2026, and the company had a of $115.5M as of June 30, 2026.
From time to time, we may be subject to litigation and claims arising in the ordinary course of business, which could have a material adverse effect on our business, operating results, cash flows or financial condition. Please refer to Note 16, Commitments and Contingencies of o…
⌄
From time to time, we may be subject to litigation and claims arising in the ordinary course of business, which could have a material adverse effect on our business, operating results, cash flows or financial condition. Please refer to Note 16, Commitments and Contingencies of our unaudited condensed consolidated financial statements in Part I, Item 1 of this Quarterly Report for information regarding material legal proceedings.
In addition, in February 2024, we became aware that the SEC had initiated a formal investigation involving the Company and certain of its directors and officers. This formal investigation relates to the Company’s public disclosures, including about product sales and the receipt of a Form 483 by an investigator at one of the Company’s clinical trial sites in the TRANQUILITY II study, and trading in the securities of the Company. We are cooperating fully with the investigation including producing documents, and current and former officers and employees of the Company have testified before the SEC. We cannot predict or determine whether any proceeding may be instituted by the SEC in connection with its investigation or the outcome of any proceeding that may be instituted, or the effects any such proceeding could have on the Company’s business or financing efforts.
Substantial doubt exists about the company's ability to continue as a going concern, requiring near-term strategic transactions to address liquidity and debt.
⌄
The company has raised substantial doubt about its ability to continue as a , with cash of $13.8 million as of June 30, 2026, only sufficient to fund operations through August 2026.
A in the Twelfth Amendment to the Credit Agreement requires the company to enter into definitive agreements for a strategic transaction acceptable to lenders by August 21, 2026, to address its $107.2 million in debt.
The company is heavily dependent on the success of its sole approved product, IGALMI®, and its lead product candidate, BXCL501, while facing significant regulatory and clinical development setbacks, including FDA requirements for additional efficacy and safety data for BXCL501 in Alzheimer's-related agitation.
Newly emphasized U.S. tariffs on imported patented pharmaceuticals, effective July 31, 2026, could materially increase manufacturing costs for IGALMI® and its active ingredient.
The company is subject to ongoing securities class action and stockholder derivative litigation, as well as an SEC investigation, related to disclosures about its TRANQUILITY II clinical trial and product sales.
Workforce reductions of approximately 60% in 2023 and a further 50% in 2024 as part of a clinical reprioritization may lead to loss of expertise, operational challenges, and difficulty in attracting talent.